Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRADITiONAL: TETA 4HCl vs DPA in Wilson's Disease
NCT07465718Phase 3Recruiting
- Sponsor
- Orphalan
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of trientine tetrahydrochloride in Wilson's disease, sponsored by Orphalan. Started Sep 2026; status: recruiting.
02
Drugs
trientine tetrahydrochloride
03
Conditions
Wilson's disease
Beyond the preview
Go deeper on NCT07465718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465718.